Phase	phase	O	O	O	O
II	ii	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
amsacrine	amsacrine	O	O	OTHERS	I
analogue	analogue	O	O	O	O
CI-921	ci-921	O	O	OTHERS	I
(	(	O	O	O	O
NSC	nsc	O	O	OTHERS	I
343499	343499	O	O	OTHERS	I
)	)	O	O	O	O
in	in	O	O	O	O
non-small	non-small	O	O	O	O
cell	cell	O	O	O	O
lung	lung	O	O	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
.	.	O	O	O	O

CI-921	ci-921	O	O	OTHERS	I
(	(	O	O	O	O
NSC	nsc	O	O	OTHERS	I
343499	343499	O	O	OTHERS	I
;	;	O	O	O	O
9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino	9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino	CHEMICALS	O	OTHERS	I
]	]	CHEMICALS	O	OTHERS	I
-N,5-dimethyl-	-n,5-dimethyl-	CHEMICALS	O	OTHERS	I
4-acridinecarboxamide	4-acridinecarboxamide	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
topoisomerase	topoisomerase	O	O	O	O
II	ii	O	O	O	O
poison	poison	O	O	O	O
with	with	O	O	O	O
high	high	O	O	O	O
experimental	experimental	O	O	O	O
antitumour	antitumour	O	O	O	O
activity	activity	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
was	was	O	O	O	O
administered	administered	O	O	O	O
by	by	O	O	O	O
15	15	O	O	O	O
min	min	O	O	O	O
infusion	infusion	O	O	O	O
to	to	O	O	O	O
16	16	O	O	O	O
evaluable	evaluable	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
non-small	non-small	O	O	O	O
cell	cell	O	O	O	O
lung	lung	O	O	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
(	(	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
)	)	O	O	O	O
(	(	O	O	O	O
7	7	O	O	O	O
with	with	O	O	O	O
no	no	O	O	O	O
prior	prior	O	O	O	O
treatment	treatment	O	O	O	O
,	,	O	O	O	O
9	9	O	O	O	O
patients	patients	O	O	O	O
in	in	O	O	O	O
relapse	relapse	O	O	O	O
following	following	O	O	O	O
surgery/radiotherapy	surgery/radiotherapy	O	O	O	O
)	)	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
dose	dose	O	O	O	O
(	(	O	O	O	O
648	648	O	O	O	O
mg/m2	mg/m2	O	O	O	O
divided	divided	O	O	O	O
over	over	O	O	O	O
3	3	O	O	O	O
days	days	O	O	O	O
,	,	O	O	O	O
repeated	repeated	O	O	O	O
every	every	O	O	O	O
3	3	O	O	O	O
weeks	weeks	O	O	O	O
)	)	O	O	O	O
determined	determined	O	O	O	O
by	by	O	O	O	O
phase	phase	O	O	O	O
I	i	O	O	O	O
trial	trial	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
median	median	O	O	O	O
performance	performance	O	O	O	O
status	status	O	O	O	O
of	of	O	O	O	O
1	1	O	O	O	O
(	(	O	O	O	O
WHO	who	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
median	median	O	O	O	O
age	age	O	O	O	O
of	of	O	O	O	O
61	61	O	O	O	O
years	years	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
histology	histology	O	O	O	O
comprised	comprised	O	O	O	O
squamous	squamous	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
(	(	O	O	O	O
11	11	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
adenocarcinoma	adenocarcinoma	O	O	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
mixed	mixed	O	O	O	O
histology	histology	O	O	O	O
(	(	O	O	O	O
2	2	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
bronchio-alveolar	bronchio-alveolar	O	O	O	O
carcinoma	carcinoma	O	DISEASE	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
large	large	O	O	O	O
cell	cell	O	O	O	O
undifferentiated	undifferentiated	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Neutropenia	neutropenia	O	DISEASE	OTHERS	I
grade	grade	O	O	O	O
greater	greater	O	O	O	O
than	than	O	O	O	O
or	or	O	O	O	O
equal	equal	O	O	O	O
to	to	O	O	O	O
3	3	O	O	O	O
was	was	O	O	O	O
seen	seen	O	O	O	O
in	in	O	O	O	O
15	15	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
infections	infections	O	DISEASE	OTHERS	I
with	with	O	O	O	O
recovery	recovery	O	O	O	O
in	in	O	O	O	O
3	3	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
grand	grand	O	O	OTHERS	I
mal	mal	O	O	OTHERS	I
seizures	seizures	O	DISEASE	OTHERS	I
in	in	O	O	O	O
1	1	O	O	O	O
patient	patient	O	O	O	O
.	.	O	O	O	O

Grade	grade	O	O	O	O
less	less	O	O	O	O
than	than	O	O	O	O
or	or	O	O	O	O
equal	equal	O	O	O	O
to	to	O	O	O	O
2	2	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
and	and	O	O	O	O
vomiting	vomiting	O	DISEASE	OTHERS	I
occurred	occurred	O	O	O	O
in	in	O	O	O	O
66	66	O	O	O	O
%	%	O	O	O	O
courses	courses	O	O	O	O
and	and	O	O	O	O
phlebitis	phlebitis	O	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
infusion	infusion	O	O	O	O
arm	arm	O	O	O	O
in	in	O	O	O	O
37	37	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O

1	1	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
squamous	squamous	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
achieved	achieved	O	O	O	O
a	a	O	O	O	O
partial	partial	O	O	O	O
response	response	O	O	O	O
lasting	lasting	O	O	O	O
5	5	O	O	O	O
months	months	O	O	O	O
.	.	O	O	O	O

Further	further	O	O	O	O
testing	testing	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
and	and	O	O	O	O
other	other	O	O	O	O
tumour	tumour	O	O	OTHERS	I
types	types	O	O	O	O
using	using	O	O	O	O
multiple	multiple	O	O	O	O
daily	daily	O	O	O	O
schedules	schedules	O	O	O	O
is	is	O	O	O	O
warranted	warranted	O	O	O	O
.	.	O	O	O	O

